SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced results from three preclinical studies related to its ongoing research and development programs. The data are being presented this week at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California.
Help employers find you! Check out all the jobs and post your resume.
